BVX.L

BiVictriX Therapeutics plc
BiVictriX Therapcts. - Grant of Options
13th August 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 1629A
BiVictriX Therapeutics PLC
13 August 2024
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

 

Grant of Options

PDMR/Director Dealings

 

Alderley Park, 13 August 2024 - BiVictriX Therapeutics plc (AIM: BVX), a drug discovery and development company applying an innovative, proprietary approach to develop a new class of highly selective, next generation cancer therapeutics, bispecific antibody drug conjugates (Bi-Cygni® ADCs), which exhibit superior potency, whilst reducing treatment-related toxicities, announces a grant of options over an aggregate of 2,717,776 ordinary shares of 1 pence each in the capital of the Company (the "Options") to certain Directors/PDMRs of the Company.

 

The Options have an exercise price of 13 pence each, and will either vest over three years, or be subject to the achievement of strategic corporate and financial goals that the Board believes will create value for Shareholders. The Options will expire ten years from the date of grant.

 

The Options have been awarded upon the recommendation of the Company's Remuneration Committee and pursuant to the terms of the Company's Share Option Plan, which was updated and adopted on 28 March 2024.

 

As part of this review and grant of Options, 1,032,667 of Tiffany Thorn's previously awarded options, which were awarded at the time of the IPO in August 2021, and were aligned to performance criteria, have subsequently been cancelled due to the performance conditions assigned to them no longer being regarded as appropriate for the business.

 

 The following Options have been granted to Directors/PDMRs of the Company:

 

Director/PDMR

New Options granted

Options Cancelled

Total Options held

Tiffany Thorn

2,197,776

1,032,667

6,862,109

Susan Lowther

200,000

-

200,000

Oliver Schon

320,000

-

1,136,333

 

Following this grant of Options, the total number of ordinary shares under option is 11,113,443, representing 13.5 per cent. of the Company's total issued share capital.

 

 

ENDS

 

For more information, please contact:

 

BiVictriX Therapeutics plc



Tiffany Thorn, Chief Executive Officer

Michael Kauffman, Non-Executive Chairman 

 

Email:  info@bivictrix.com





SP Angel Corporate Finance LLP (NOMAD and Broker)

  Tel: +44 (0) 20 3470 0470


David Hignell, Caroline Rowe (Corporate Finance)

Vadim Alexandre, Rob Rees (Sales and Broking)



 

Panmure Liberum Limited (Joint Broker)

 

  Tel: +44 (0) 20 7886 2500


Rupert Dearden/Freddy Crossley/Emma Earl

 

ICR Consilium



Namrata Taak, Lucy Featherstone,

Max Bennett, Emmalee Hoppe

Tel: +44 (0) 20 3709 5700

Email:  Bivictrix@consilium-comms.com






 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or "Bi-Cygni® fingerprints", on tumour cells, which are largely absent from healthy cells.

 

BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company's novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

 

Find out more about BiVictriX online at  www.bivictrix.com   

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

1)   Tiffany Thorn

2)   Susan Lowther  

3)   Oliver Schon  

 

2. 

Reason for the Notification

a)

Position/status

1)    CEO

 

2)    Non-Executive Director

 

3)    VP, R&D

  

b)

Initial notification/Amendment

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

BiVictriX Therapeutics plc

b)

LEI

213800ZI85IZNA6N3L53

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 1 pence each

GB00BNXH3K91

Identification code


b)

Nature of the transaction

Grant of Options

c)

Price(s) and volume(s)

All Options have an exercise price of 13 pence each

Volume of Options

1 )    2,197,776

2)    200,000

3)   320,000

d)

Aggregated information:

-   Aggregated volume

-   Price

 

 

Volume:  2,717,776 Options

 

 

Exercise price of all Options: 13 pence each

e)

Date of the transaction

  13 August 2024

f)

Place of the transaction

Outside a trading venue  

 

 

 

 

 

                                       

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFZGMRGZMGDZZ]]>
TwitterFacebookLinkedIn